Cystic Fibrosis: Recent Insights into Inhaled Antibiotic Treatment and Future Perspectives

It’s Not Easy Being Green: A Narrative Review on the Microbiology, Virulence and Therapeutic Prospects of Multidrug-Resistant Pseudomonas aeruginosa

(2021) Payam Behzadi et al.   Antibiotics-Basel

Cystic fibrosis – Ten promising therapeutic approaches in the current era of care

(2020) Ranjani Somayaji et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

P150 Aztreonam lysine recovers lung function and improves quality of life in the treatment of acute exacerbations of cystic fibrosis: results from an open-label randomised crossover study (AZTEC-CF)

(2020) F. Frost et al.   Journal of Cystic Fibrosis

Untargeted Metagenomic Investigation of the Airway Microbiome of Cystic Fibrosis Patients with Moderate-Severe Lung Disease

(2020) Giovanni Bacci et al.   Microorganisms

Pulmonary exacerbations in adults with cystic fibrosis - a grown-up issue in a changing CF landscape

(2020) Gemma E. Stanford et al.   CHEST

Long-term safety study of colistimethate sodium (Colobreathe®): Findings from the UK Cystic Fibrosis Registry

(2020) Sigal Kaplan et al.   Journal of Cystic Fibrosis

Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial

(2020) Simon C Langton Hewer et al.   Lancet Respiratory Medicine

Development of elexacaftor - tezacaftor – ivacaftor: highly effective CFTR modulation for the majority of people with cystic fibrosis

(2020) Peter G Middleton et al.   Expert Review of Respiratory Medicine

Nebulized gentamicin in combination with systemic antibiotics for eradicating early Pseudomonas aeruginosa infection in children with cystic fibrosis

(2019) Ben Van Stormbroek et al.   PEDIATRIC PULMONOLOGY

Methicillin-resistant Staphylococcus aureus eradication in cystic fibrosis patients: A randomized multicenter study

(2019) Daniela Dolce et al.   PLoS One

The effects of cycled inhaled aztreonam on the cystic fibrosis (CF) lung microbiome

(2019) Alya A. Heirali et al.   Journal of Cystic Fibrosis

Anti-pseudomonad Activity of Manuka Honey and Antibiotics in a Specialized ex vivo Model Simulating Cystic Fibrosis Lung Infection

(2019) Aled E. L. Roberts et al.   Frontiers in Microbiology

Tolerance and Resistance of Pseudomonas aeruginosa Biofilms to Antimicrobial Agents—How P. aeruginosa Can Escape Antibiotics

(2019) Oana Ciofu et al.   Frontiers in Microbiology

Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis

(2019) Diana Bilton et al.   Journal of Cystic Fibrosis

Changing epidemiology of the respiratory bacteriology of patients with cystic fibrosis–data from the European cystic fibrosis society patient registry

(2019) Elpis Hatziagorou et al.   Journal of Cystic Fibrosis

Deciphering the Ecology of Cystic Fibrosis Bacterial Communities: Towards Systems-Level Integration

(2019) Annamaria Bevivino et al.   TRENDS IN MOLECULAR MEDICINE

Antimicrobial Treatment of Staphylococcus aureus in Patients With Cystic Fibrosis

(2019) Susanna Esposito et al.   Frontiers in Pharmacology

Antimicrobial resistance in cystic fibrosis: A Delphi approach to defining best practices

(2019) Edith Zemanick et al.   Journal of Cystic Fibrosis

Acute Pulmonary Exacerbations in Cystic Fibrosis

(2019) Christopher H. Goss   SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE

Tezacaftor and ivacaftor for the treatment of cystic fibrosis

(2019) Sarah L. Paterson et al.   Expert Review of Respiratory Medicine

Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis: The Optimize Randomized Trial

(2018) Nicole Mayer-Hamblett et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

OUP accepted manuscript

(2018)   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Eradication of early P. aeruginosa infection in children

(2018) Felix Ratjen et al.   Journal of Cystic Fibrosis

ECFS best practice guidelines: the 2018 revision

(2018) Carlo Castellani et al.   Journal of Cystic Fibrosis

PEGylation of Tobramycin Improves Mucus Penetration and Antimicrobial Activity against Pseudomonas aeruginosa Biofilms in Vitro

(2018) Tania F. Bahamondez-Canas et al.   MOLECULAR PHARMACEUTICS

Fluctuations in airway bacterial communities associated with clinical states and disease stages in cystic fibrosis

(2018) Lisa A. Carmody et al.   PLoS One

Successful eradication of newly acquired MRSA in six of seven patients with cystic fibrosis applying a short-term local and systemic antibiotic scheme

(2018) Alexander Kiefer et al.   BMC Pulmonary Medicine

Implementation of a successful eradication protocol for Burkholderia Cepacia complex in cystic fibrosis patients

(2018) Bryan A. Garcia et al.   BMC Pulmonary Medicine

Staphylococcus aureus in cystic fibrosis

(2018) Matthew N. Hurley et al.   CURRENT OPINION IN PULMONARY MEDICINE

New anti-pseudomonal agents for cystic fibrosis- still needed in the era of small molecule CFTR modulators?

(2018) Jane C. Davies et al.   EXPERT OPINION ON PHARMACOTHERAPY

Eradication of persistent methicillin-resistant Staphylococcus aureus infection in cystic fibrosis

(2018) Rebecca Dezube et al.   Journal of Cystic Fibrosis

Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis

(2017) Dave P. Nichols et al.   Journal of Cystic Fibrosis

Effectiveness of a stepwise Pseudomonas aeruginosa eradication protocol in children with cystic fibrosis

(2017) Ana C. Blanchard et al.   Journal of Cystic Fibrosis

Use of FEV 1 in cystic fibrosis epidemiologic studies and clinical trials: A statistical perspective for the clinical researcher

(2017) Rhonda Szczesniak et al.   Journal of Cystic Fibrosis

The fate of inhaled antibiotics after deposition in cystic fibrosis: How to get drug to the bug?

(2017) Aukje C. Bos et al.   Journal of Cystic Fibrosis

Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence

(2017) Kamal Hamed et al.   Therapeutic Advances in Respiratory Disease

The effects of inhaled aztreonam on the cystic fibrosis lung microbiome

(2017) Alya A. Heirali et al.   Microbiome

Staphylococcus aureus interaction with Pseudomonas aeruginosa biofilm enhances tobramycin resistance

(2017) T. Beaudoin et al.   npj Biofilms and Microbiomes

Sequential Treatment of Biofilms with Aztreonam and Tobramycin Is a Novel Strategy for Combating Pseudomonas aeruginosa Chronic Respiratory Infections

(2016) Estrella Rojo-Molinero et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comparison of Inhaled Antibiotics for the Treatment of Chronic Pseudomonas aeruginosa Lung Infection in Patients With Cystic Fibrosis: Systematic Literature Review and Network Meta-analysis

(2016) J. Stuart Elborn et al.   CLINICAL THERAPEUTICS

The Microbiome in Cystic Fibrosis

(2016) Yvonne J. Huang et al.   CLINICS IN CHEST MEDICINE

Production of extended-spectrum β -lactamases and the potential indirect pathogenic role of Prevotella isolates from the cystic fibrosis respiratory microbiota

(2016) Laura J. Sherrard et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis

(2016) Patrick A. Flume et al.   Journal of Cystic Fibrosis

Improving inhaled antibiotic treatment – Practice defeats the proof

(2016) C Kors van der Ent et al.   Journal of Cystic Fibrosis

Continuous alternating inhaled antibiotic therapy in CF: A single center retrospective analysis

(2016) C. Van de Kerkhove et al.   Journal of Cystic Fibrosis

Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection

(2016) J. Stuart Elborn et al.   Journal of Cystic Fibrosis

Eradication failure of newly acquired Pseudomonas aeruginosa isolates in cystic fibrosis

(2016) Malena Cohen-Cymberknoh et al.   Journal of Cystic Fibrosis

A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients

(2016) Patrick A. Flume et al.   Journal of Cystic Fibrosis

Pediatric Pulmonology

(2016)   PEDIATRIC PULMONOLOGY

Eradication of methicillin resistantStaphylococcus aureusdetected for the first time in cystic fibrosis: A single center observational study

(2016) Matthias Kappler et al.   PEDIATRIC PULMONOLOGY

Respiratory syncytial virus infection enhancesPseudomonas aeruginosabiofilm growth through dysregulation of nutritional immunity

(2016) Matthew R. Hendricks et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Microbiological efficacy of early MRSA treatment in cystic fibrosis in a randomised controlled trial

(2016) Marianne Sponer Muhlebach et al.   THORAX

Inhaled antibiotics for the treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis patients: challenges to treatment adherence and strategies to improve outcomes

(2016) Réka Bodnár et al.   Patient Preference and Adherence

New Inhaled Antimicrobial Formulations for Use in the Cystic Fibrosis Patient Population

(2015) Christopher T. Campbell et al.   ANNALS OF PHARMACOTHERAPY

Mucin Binding Reduces Colistin Antimicrobial Activity

(2015) Johnny X. Huang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Novel inhaled combined antibiotic formulations in the treatment ofPseudomonas aeruginosaairways infections in cystic fibrosis

(2015) Sabina Antoniu   Expert Review of Anti-Infective Therapy

Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: Formulation, characterisation and functionalisation with dornase alfa (DNase)

(2015) Jill Deacon et al.   JOURNAL OF CONTROLLED RELEASE

Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes

(2015) Elliott C. Dasenbrook et al.   Journal of Cystic Fibrosis

A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients

(2015) J. Stuart Elborn et al.   Journal of Cystic Fibrosis

The daily dynamics of cystic fibrosis airway microbiota during clinical stability and at exacerbation

(2015) Lisa A Carmody et al.   Microbiome

Longevity of Patients With Cystic Fibrosis in 2000 to 2010 and Beyond: Survival Analysis of the Cystic Fibrosis Foundation Patient Registry

(2014) Todd MacKenzie et al.   ANNALS OF INTERNAL MEDICINE

Pyrosequencing reveals transient cystic fibrosis lung microbiome changes with intravenous antibiotics

(2014) D. J. Smith et al.   EUROPEAN RESPIRATORY JOURNAL

Mechanisms of reduced susceptibility and genotypic prediction of antibiotic resistance in Prevotella isolated from cystic fibrosis (CF) and non-CF patients

(2014) Laura J Sherrard et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Antimicrobial resistance in the respiratory microbiota of people with cystic fibrosis

(2014) Laura J Sherrard et al.   LANCET

Early treatment with inhaled antibiotics postpones next occurrence of Achromobacter in cystic fibrosis

(2013) M. Wang et al.   Journal of Cystic Fibrosis

Inhaled aztreonam for chronic Burkholderia infection in cystic fibrosis: A placebo-controlled trial

(2013) D. Elizabeth Tullis et al.   Journal of Cystic Fibrosis

Treatment of lung infection in patients with cystic fibrosis: Current and future strategies

(2012) Gerd Döring et al.   Journal of Cystic Fibrosis

Eradication therapy for Pseudomonas aeruginosa colonization episodes in cystic fibrosis patients not chronically colonized by P. aeruginosa

(2012) Petra Schelstraete et al.   Journal of Cystic Fibrosis

Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: A comparative efficacy trial

(2012) Baroukh M. Assael et al.   Journal of Cystic Fibrosis

Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study

(2012) Antje Schuster et al.   THORAX

Levofloxacin Inhalation Solution (MP-376) in Patients with Cystic Fibrosis withPseudomonas aeruginosa

(2011) David E. Geller et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Managing Cystic Fibrosis

(2011) Malena Cohen-Cymberknoh et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Pharmacokinetics and Safety of MP-376 (Levofloxacin Inhalation Solution) in Cystic Fibrosis Subjects

(2011) David E. Geller et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comparative Efficacy and Safety of 4 Randomized Regimens to Treat Early Pseudomonas aeruginosa Infection in Children With Cystic Fibrosis

(2011) Miriam M. Treggiari   ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE

Update on methicillin-resistant Staphylococcus aureus in cystic fibrosis

(2011) Elliott C. Dasenbrook   CURRENT OPINION IN PULMONARY MEDICINE

Marked increase in incidence of Achromobacter xylosoxidans infections caused by sporadic acquisition from the environment

(2011) Winnie Ridderberg et al.   Journal of Cystic Fibrosis

Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa

(2011) C.E. Wainwright et al.   Journal of Cystic Fibrosis

Association Between Respiratory Tract Methicillin-Resistant Staphylococcus aureus and Survival in Cystic Fibrosis

(2010) Elliott C. Dasenbrook   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial

(2010) Michael W. Konstan et al.   Journal of Cystic Fibrosis

Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: The EVOLVE trial

(2010) Michael W. Konstan et al.   PEDIATRIC PULMONOLOGY

An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis

(2010) Christopher M. Oermann et al.   PEDIATRIC PULMONOLOGY

Aztreonam lysine: a novel inhalational antibiotic for cystic fibrosis

(2010) Michael D Parkins et al.   Expert Review of Respiratory Medicine

Cystic Fibrosis Pulmonary Guidelines

(2009) Patrick A. Flume et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

In Vitro Pharmacodynamics of Levofloxacin and Other Aerosolized Antibiotics under Multiple Conditions Relevant to Chronic Pulmonary Infection in Cystic Fibrosis

(2009) P. King et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy and Safety of Inhaled Aztreonam Lysine for Airway Pseudomonas in Cystic Fibrosis

(2009) George Z. Retsch-Bogart et al.   CHEST

Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial

(2009) F. Ratjen et al.   THORAX

Inhaled Aztreonam Lysine for Chronic AirwayPseudomonas aeruginosain Cystic Fibrosis

(2008) Karen S. McCoy et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Prevalence and Impact of Respiratory Viral Infections in Young Children With Cystic Fibrosis: Prospective Cohort Study

(2008) B. E. van Ewijk et al.   PEDIATRICS

Aerosolized antibiotics in cystic fibrosis: current and future trends

(2008) Stanley B Fiel   Expert Review of Respiratory Medicine